FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281563445> ?p ?o ?g. }

• W4281563445 endingPage "2040" @default.
• W4281563445 startingPage "2031" @default.
• W4281563445 abstract "Abstract Backgrounds The PACIFIC trial established durvalumab consolidation therapy after concurrent chemoradiotherapy (CCRT) as the standard treatment for locally advanced non–small cell lung cancer (LA‐NSCLC). However, little is known about the predictive factors of durvalumab efficacy in this population. This study aimed to validate the predictive use of inflammation‐related parameters in patients with LA‐NSCLC treated with CCRT plus durvalumab. Methods We recruited 76 LA‐NSCLC patients who received CCRT followed by durvalumab from 10 Japanese institutions. The neutrophil‐to‐lymphocyte ratio (NLR), C‐reactive protein‐to‐albumin ratio (CAR), and prognostic nutrition index (PNI) were measured before (pre‐treatment) and 2 months after (post‐treatment) durvalumab induction. Cox proportional hazards analysis was used to examine prognostic factors associated with progression‐free survival (PFS) after durvalumab therapy. Results The median follow‐up time was 17 (range, 3.3–35.8) months. The median PFS and overall survival (OS) times were 26.1 and 33.7 months, respectively. Durvalumab was discontinued in 47 (61.8%) patients, with non‐infectious pneumonitis being the most common reason. Post‐treatment CAR (cutoff, 0.2) was a significant stratifying factor in survival comparison (<0.2 vs. ≥ 0.2, median PFS, not‐reached vs. 9.6 months. Log‐rank, p = 0.002). Multivariate analysis with a Cox proportional hazards model showed that post‐treatment CAR was an independent prognostic factor for PFS (hazard ratio, 3.16, p = 0.003). Conclusions This study suggests that post‐treatment CAR has predictive value for LA‐NSCLC patients treated with CCRT plus durvalumab consolidation therapy." @default.
• W4281563445 created "2022-05-27" @default.
• W4281563445 creator A5003341249 @default.
• W4281563445 creator A5003450974 @default.
• W4281563445 creator A5015470061 @default.
• W4281563445 creator A5018916035 @default.
• W4281563445 creator A5021706921 @default.
• W4281563445 creator A5030272462 @default.
• W4281563445 creator A5033304177 @default.
• W4281563445 creator A5033961075 @default.
• W4281563445 creator A5037562978 @default.
• W4281563445 creator A5045092333 @default.
• W4281563445 creator A5045306434 @default.
• W4281563445 creator A5049063246 @default.
• W4281563445 creator A5049289729 @default.
• W4281563445 creator A5057680540 @default.
• W4281563445 creator A5072113018 @default.
• W4281563445 creator A5074715381 @default.
• W4281563445 date "2022-05-26" @default.
• W4281563445 modified "2023-10-17" @default.
• W4281563445 title "Predictive value of <scp>post‐treatment C‐reactive protein‐to‐albumin</scp> ratio in locally advanced <scp>non–small</scp> cell lung cancer patients receiving durvalumab after chemoradiotherapy" @default.
• W4281563445 cites W1550108534 @default.
• W4281563445 cites W1965037168 @default.
• W4281563445 cites W2019607817 @default.
• W4281563445 cites W2022837929 @default.
• W4281563445 cites W2033658212 @default.
• W4281563445 cites W2052727153 @default.
• W4281563445 cites W2066562433 @default.
• W4281563445 cites W2068362347 @default.
• W4281563445 cites W2104701073 @default.
• W4281563445 cites W2121960517 @default.
• W4281563445 cites W2141955497 @default.
• W4281563445 cites W2228221433 @default.
• W4281563445 cites W2253806401 @default.
• W4281563445 cites W2591717879 @default.
• W4281563445 cites W2613441698 @default.
• W4281563445 cites W2613465540 @default.
• W4281563445 cites W2618641368 @default.
• W4281563445 cites W2737656823 @default.
• W4281563445 cites W2753065806 @default.
• W4281563445 cites W2785431528 @default.
• W4281563445 cites W2887632081 @default.
• W4281563445 cites W2897840670 @default.
• W4281563445 cites W2898345296 @default.
• W4281563445 cites W2941271487 @default.
• W4281563445 cites W2965190971 @default.
• W4281563445 cites W3010768695 @default.
• W4281563445 cites W3015115081 @default.
• W4281563445 cites W3016080515 @default.
• W4281563445 cites W3022919793 @default.
• W4281563445 cites W3087266846 @default.
• W4281563445 cites W3095739337 @default.
• W4281563445 cites W3120682952 @default.
• W4281563445 cites W3178448769 @default.
• W4281563445 cites W3183813669 @default.
• W4281563445 cites W3210047836 @default.
• W4281563445 cites W3214742056 @default.
• W4281563445 cites W4220893576 @default.
• W4281563445 cites W4226175083 @default.
• W4281563445 cites W4281563445 @default.
• W4281563445 doi "https://doi.org/10.1111/1759-7714.14484" @default.
• W4281563445 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35616056" @default.
• W4281563445 hasPublicationYear "2022" @default.
• W4281563445 type Work @default.
• W4281563445 citedByCount "8" @default.
• W4281563445 countsByYear W42815634452022 @default.
• W4281563445 countsByYear W42815634452023 @default.
• W4281563445 crossrefType "journal-article" @default.
• W4281563445 hasAuthorship W4281563445A5003341249 @default.
• W4281563445 hasAuthorship W4281563445A5003450974 @default.
• W4281563445 hasAuthorship W4281563445A5015470061 @default.
• W4281563445 hasAuthorship W4281563445A5018916035 @default.
• W4281563445 hasAuthorship W4281563445A5021706921 @default.
• W4281563445 hasAuthorship W4281563445A5030272462 @default.
• W4281563445 hasAuthorship W4281563445A5033304177 @default.
• W4281563445 hasAuthorship W4281563445A5033961075 @default.
• W4281563445 hasAuthorship W4281563445A5037562978 @default.
• W4281563445 hasAuthorship W4281563445A5045092333 @default.
• W4281563445 hasAuthorship W4281563445A5045306434 @default.
• W4281563445 hasAuthorship W4281563445A5049063246 @default.
• W4281563445 hasAuthorship W4281563445A5049289729 @default.
• W4281563445 hasAuthorship W4281563445A5057680540 @default.
• W4281563445 hasAuthorship W4281563445A5072113018 @default.
• W4281563445 hasAuthorship W4281563445A5074715381 @default.
• W4281563445 hasBestOaLocation W42815634452 @default.
• W4281563445 hasConcept C121608353 @default.
• W4281563445 hasConcept C126322002 @default.
• W4281563445 hasConcept C143998085 @default.
• W4281563445 hasConcept C207103383 @default.
• W4281563445 hasConcept C2776256026 @default.
• W4281563445 hasConcept C2777701055 @default.
• W4281563445 hasConcept C2777742743 @default.
• W4281563445 hasConcept C2778424827 @default.
• W4281563445 hasConcept C2780030458 @default.
• W4281563445 hasConcept C44249647 @default.
• W4281563445 hasConcept C50382708 @default.
• W4281563445 hasConcept C71924100 @default.
• W4281563445 hasConceptScore W4281563445C121608353 @default.

• next